Lantus SoloStar 与 Tequin
Lantus SoloStar 与 Tequin互相作用以及同时服用的可能性。
在该服务的官方手册中,已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果,或起到良好效果。具体联合用药问题,需遵从医嘱。
用户:沙星可能会影响血液中的葡萄糖水平,不应该用在患有糖尿病。 两血糖过低(低血糖),较不频繁,高血糖(高血糖)的报告。 严重的情况下低血糖的治疗期间,沙星导致昏迷甚至死亡。 谈谈你的医生如果你有任何疑问或关切的问题。 你的医生可以规定替代品,不进行互动。 重要的是要告诉你的医生关于所有其他药物的使用,包括维生素和草药。 不停止使用任何药物,没有第一个说你的医生。
医界专家:禁忌:沙星可能会干扰治疗作用的胰岛素和其他抗糖尿病剂。 使用各种药物有关的干扰,在血液中的葡萄糖的动态平衡可能产生的影响的胰β细胞ATP敏感钾的渠道,调节胰岛素分泌. 然而,低血糖和高血糖,已报告更频繁地与沙星于其他种药物. 沙星致降低血糖的事件通常发生在第3天的治疗,有时甚至后的第一次剂量,同时高血糖通常发生的4到10天后开始治疗。 死亡已经报告了在严重的情况下。 共同给予的沙星用磺酰脲(最常优降糖)和/或其他口头降血糖药造成的严重、难的低血糖和血糖过低昏迷。 老年患者和患有肾功能降低特别容易受到影响。
管理:利用沙星是禁忌的糖尿病患者。 其他种药物可以较安全的替代品,在这样的病人,尽管所有种药物应当谨慎使用。 血液中的葡萄糖应密切监测,每当种药物,规定对患者接受胰岛素或其他抗糖尿病剂,特别是如果他们是老年人或有肾损伤。 患者应该学会认识到低血糖症的症状,例如头疼、头晕、睡意、紧张、混乱、震颤、饥饿、弱点、出汗,心悸,而性心动过速。 如果低或高血糖的过程中发生的诺酮治疗、患者应开始适当的补救治疗,立即停止抗生素,接触他们的医生。
- Greenberg AL, Decerbo M, Fan J "Gatifloxacin therapy associated with hypoglycemia." Clin Infect Dis 40 (2005): 1210-1
- Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000): s76-86
- Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006): 1352-61
- Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004): 111-7
- "Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003): 64
- Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC "Gatifloxacin-induced hyperglycemia." Ann Intern Med 141 (2004): 968-9
- LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004): 926-31
- Blommel AL, Lutes RA "Severe hyperglycemia during renally adjusted gatifloxacin therapy." Ann Pharmacother 39 (2005): 1349-52
- Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004): 455-7
- Yip C, Lee AJ "Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature." Clin Ther 28 (2006): 1857-66
- Tomita T, Onishi M, Sato E, Kimura Y, Kihira K "Gatifloxacin induces augmented insulin release and intracellular insulin." Biol Pharm Bull 30 (2007): 644-7
- Zhanel GG, Fontaine S, Adam H, et al. "A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections." Treat Respir Med 5 (2006): 437-465
- Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004): 602-5
- Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001): 3-8
- Zvonar R "Gatifloxacin-induced dysglycemia." Am J Health Syst Pharm 63 (2006): 2087-2092
- "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.
- Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005): 250-3
- Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002): 1722-6
- Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002): 232-4
- Graumlich JF, Habis S, Avelino RR, et al. "Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study." Pharmacotherapy 25 (2005): 1296-302
- Letourneau G, Morrison H, McMorran M "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1" ([2003 Jul]):
- Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004): 295-7
- Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000): 160-3
- Khovidhunkit W, Sunthornyothin S "Hypoglycemia, hyperglycemia, and gatifloxacin." Ann Intern Med 141 (2004): 969
- Brogan SE, Cahalan MK "Gatifloxacin as a possible cause of serious postoperative hypoglycemia." Anesth Analg 101 (2005): 635-6
- Gavin JR 3rd, Kubin R, Choudhri S, et al "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004): 671-86
- Frothingham R "Glucose homeostasis abnormalities associated with use of gatifloxacin." Clin Infect Dis 41 (2005): 1269-76
非专利名称: insulin glargine
品牌: Basaglar KwikPen, Lantus, Lantus Solostar Pen, Toujeo SoloStar, Lantus OptiClik Cartridge, Toujeo Max SoloStar, Lantus SoloStar
同义词: Lantus Solostar Pen
在药物相容性与互相作用的检测过程中使用下列的信息来源:Drugs.com, Rxlist.com, Webmd.com, Medscape.com。
- Lantus SoloStar-Terazosin
- Lantus SoloStar-Terazosin Hydrochloride
- Lantus SoloStar-Terbinafine
- Lantus SoloStar-Terbinafine (Systemic)
- Lantus SoloStar-Terbinafine Hydrochloride
- Lantus SoloStar-Terbinafine Oral Granules
- Tequin-Lantus SoloStar (Insulin Glargine (U-100) Cartridge Systems and Pens)
- Tequin-Lantus Solostar (Insulin Glargine (U-300) Pens)
- Tequin-Lantus Solostar Pen
- Tequin-Lapatinib
- Tequin-Lapatinib Ditosylate
- Tequin-Lariam